Lexeo Therapeutics (LXEO) Projected to Post Quarterly Earnings on Monday

Key Points

• Lexeo Therapeutics is set to release its Q2 2025 earnings report on August 11th, with analysts predicting an earnings per share (EPS) of ($0.61).
• In its last earnings report, Lexeo missed estimates with an EPS of ($0.99), falling short of the expected ($0.80).
• Wall Street analysts have mixed views on Lexeo, with a consensus buy rating and a price target averaging $17.17, although JPMorgan recently lowered its target from $16.00 to $10.00.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Monday, August 11th. Analysts expect Lexeo Therapeutics to post earnings of ($0.61) per share for the quarter.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.19). On average, analysts expect Lexeo Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Lexeo Therapeutics Stock Up 0.4%

LXEO traded up $0.02 during trading on Monday, reaching $4.63. The stock had a trading volume of 40,659 shares, compared to its average volume of 674,330. The company has a current ratio of 3.42, a quick ratio of 3.42 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a one year low of $1.45 and a one year high of $12.95. The company has a market capitalization of $153.70 million, a price-to-earnings ratio of -1.40 and a beta of 1.35. The stock's 50 day moving average is $3.99 and its two-hundred day moving average is $3.72.

Institutional Trading of Lexeo Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers boosted its position in shares of Lexeo Therapeutics by 19.8% during the first quarter. Rhumbline Advisers now owns 30,192 shares of the company's stock worth $105,000 after buying an additional 4,995 shares during the period. Acadian Asset Management LLC acquired a new stake in Lexeo Therapeutics during the 1st quarter valued at $85,000. AQR Capital Management LLC grew its holdings in shares of Lexeo Therapeutics by 370.0% during the 1st quarter. AQR Capital Management LLC now owns 50,337 shares of the company's stock valued at $175,000 after acquiring an additional 39,627 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in shares of Lexeo Therapeutics by 654.8% in the first quarter. Millennium Management LLC now owns 1,071,489 shares of the company's stock valued at $3,718,000 after buying an additional 929,538 shares during the period. 60.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on LXEO shares. JPMorgan Chase & Co. cut their price objective on Lexeo Therapeutics from $16.00 to $10.00 and set an "overweight" rating on the stock in a report on Friday, May 30th. Oppenheimer began coverage on Lexeo Therapeutics in a research report on Thursday. They set an "outperform" rating and a $20.00 price objective on the stock. Chardan Capital reduced their price objective on Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Finally, HC Wainwright decreased their price target on Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $17.17.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.